Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | RNASEL | Q05823 | 7/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.42 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.42 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22348916 | 1.00 | ENPP1 (0.46) | ENPP1RNASELP2RX3P2RX4P2RX2 | |
| SCHEMBL22348933 | 0.95 | ENPP1 (0.45) | ENPP1RNASELP2RX3P2RX4P2RX2 | |
| SCHEMBL17948724 | 0.95 | ENPP1 (0.45) | ENPP1RNASELP2RX3P2RX4P2RX2 | |
| SCHEMBL22348902 | 0.95 | ENPP1 (0.45) | ENPP1RNASELP2RX3P2RX4P2RX2 | |
| SCHEMBL17948712 | 0.94 | ENPP1 (0.45) | ENPP1RNASELP2RX3P2RX4P2RX2 | |
| SCHEMBL22348928 | 0.94 | ENPP1 (0.45) | ENPP1RNASELP2RX3P2RX4P2RX2 | |
| SCHEMBL22348927 | 0.94 | ENPP1 (0.45) | ENPP1RNASELP2RX3P2RX4P2RX2 | |
| SCHEMBL16568374 | 0.93 | RNASEL (0.44) | ENPP1RNASEL | |
| SCHEMBL16568365 | 0.93 | RNASEL (0.44) | ENPP1RNASEL | |
| SCHEMBL15083421 | 0.93 | RNASEL (0.44) | ENPP1RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046194-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046194-A1 | Ribosome-Mediated Incorporation of Peptides and Peptidomimetics | NPEPPS, DNPEP, AARS1 | ENPP1 2802/4885RNASEL 663/4885P2RX3 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.